RxDoctor Payments Data

Phillip Campanella

Adult Health · Matawan, NJNPI 1013609890

Payments from drug & device makers

$1,878in general payments, 2019–2025

Across 55 payments — averaging $34.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$367
  • AstraZeneca$335
  • Johnson & Johnson$269
  • Pfizer$250
  • E.r. Squibb & Sons, L.L.C.$217
  • Novartis$161
  • plus $279 from 3 others

What the payments were for

  • Food & beverage$1,878100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,878 in reported general payments places this provider in the 80th percentile of 1,135 adult health providers in New Jersey.

See all adult health providers in New Jersey

Medicare billing

Part B allowed, 2024
$12,338
Medicare patients
133
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$38,151
EntrestoSacubitril/Valsartan26$29,265
Atorvastatin Calcium56$821
Metoprolol Succinate47$711
Rosuvastatin Calcium28$551
Carvedilol34$381
Losartan Potassium24$311
Simvastatin21$281
Potassium Chloride13$229
Metoprolol Tartrate30$208
ClopidogrelClopidogrel Bisulfate15$199
Warfarin Sodium14$185
Isosorbide Mononitrate ErIsosorbide Mononitrate11$176
Spironolactone20$138
Amlodipine Besylate19$130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$250$38,15126 claims
NovartisEntresto$161$29,26526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,135 adult health providers in New Jersey.

Other adult health in Matawan

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →